抗忧郁症市场（按药物类别、给药途径、分销管道和地区划分）

预计 2025 年全球抗忧郁症市场规模为 201.1 亿美元，到 2032 年将达到 331.6 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.4%。

数字。 2025年抗忧郁症市场占有率（按地区分列）

抗忧郁症是用于治疗重度忧郁症的药物。它用于改变大脑化学反应，以缓解悲伤、失去兴趣、内疚感或低自我价值感、睡眠问题或食慾不振、疲劳和注意力不集中等症状。忧郁症和其他精神疾病的盛行率不断提高，人们对此的认识不断提高，这加剧了全球对抗抗忧郁症的需求。此外，大型製药企业对新型先进治疗方法的开发也推动了市场的成长。然而，替代治疗方法的可用性以及抗忧郁症的副作用在一定程度上限制了市场扩张。

市场动态：

影响全球抗忧郁症市场成长的市场驱动因素包括忧郁症和其他精神疾病盛行率的上升、对忧郁症诊断和管理的认识的提高、新产品的推出以及医疗保健支出的增加。根据世界卫生组织估计，全球有超过2.64亿人患有忧郁症。以身心障碍生活年资（YLD）衡量，忧郁症也是导致失能的主要原因。此外，抗忧郁症用于治疗忧郁症以外的其他疾病（如焦虑症、创伤后压力症候群 (PTSD)、月经烦躁症 (PMDD) 和慢性疼痛）的接受度不断提高，也推动了市场的成长。然而，心理治疗、电痉挛疗法和社会支持等替代治疗方法的出现，限制了全球对抗抗忧郁症的完全依赖。此外，许多人在使用抗忧郁症后会出现轻微至严重的副作用，包括失眠、性功能障碍、体重变化、胃肠道问题和头痛，这限制了药物的依从性和整体市场收益。新型抗忧郁症的高成本也阻碍了市场发展，特别是在对价格敏感的开发中国家。学名药开发为满足预算受限的消费者的未满足需求提供了机会。

本研究的主要特点

本报告对全球抗忧郁症市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模（以十亿美元为单位）和年复合成长率（CAGR%）。

它还强调了各个领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。

它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球抗忧郁症市场的主要企业概况。

研究涉及的主要企业包括辉瑞、礼来、Astra Zeneca、GlaxoSmithKline Plc和诺华。

本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。

全球抗忧郁症市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过用于分析全球抗忧郁症市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管情景
• 收购与合作场景
• 资金筹措与投资
• PEST分析
• 波特分析

4. 全球抗忧郁症市场-COVID-19 疫情的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2021-2032 年全球抗忧郁症市场（依药物类别）

• 选择性血清素再回收抑制剂（SSRI）
• Fluoxetine
• 舍曲林
• 其他的
• 正肾上腺素再回收抑制剂（SNRI）
• 文拉法辛
• Duloxetine
• 其他的
• 三环抗忧郁药物（TCA）
• 阿米替林
• 丙咪嗪
• 其他的
• 单胺氧化酵素抑制剂（MAOI）
• 苯乙肼
• 反苯环丙胺
• 其他的
• 非典型抗忧郁症
• 安非他酮
• 曲唑酮
• 其他的

6. 全球抗忧郁症市场（依给药途径划分），2021-2032 年

• 口服
• 皮下
• 静脉
• 其他的

7. 全球抗忧郁症市场（依通路划分），2021-2032 年

• 医院药房
• 零售药局
• 网路药局

8. 2021-2032 年全球抗忧郁症市场（按地区）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章竞争格局

• 公司简介
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson &Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

第 10 章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第11章调查方法

• 参考
• 调查方法

Global Antidepressant Market is estimated to be valued at USD 20.11 Bn in 2025 and is expected to reach USD 33.16 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Figure. Antidepressant Market Share (%), By Region 2025

Antidepressants are medications prescribed to treat major depressive disorders. They are used to alter brain chemistry in order to relieve symptoms such as sadness, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, fatigue, and poor concentration. The increasing prevalence of depression and other mental health disorders along with growing awareness is fueling the demand for antidepressants globally. Moreover, development of new and advanced treatment options by major pharmaceutical companies is also boosting market growth. However, availability of alternative treatment methods and side-effects associated with antidepressant drugs restrict the market expansion to some extent.

Market Dynamics:

The drivers influencing growth of global antidepressant market include rising incidence of depression and other mental health conditions, growing awareness about depression diagnosis and management, new product launches, and increasing expenditure on healthcare. According to WHO, over 264 million people are estimated to suffer from depression worldwide. Depression is also the leading cause of disability as measured by Years Lived with Disability (YLDs). Furthermore, growing acceptance of antidepressants for conditions other than depression such as anxiety disorders, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and chronic pain is driving their market growth. However, availability of alternative treatment methods such as psychotherapy, electroconvulsive therapy, and social support is restricting complete reliance on antidepressants globally. Also, many individuals experience mild to serious side-effects such as insomnia, sexual dysfunction, weight changes, gastrointestinal issues, and headaches with antidepressant use, which limits their compliance and overall market revenue. High costs of new antidepressants also hinder the market growth, especially in price-sensitive developing nations. Development of generics offers opportunities to address the unmet needs of consumers with budget constraints.

Key features of the study:

This report provides in-depth analysis of the global antidepressant market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 s the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global antidepressant market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, AstraZeneca, GlaxoSmithKline, and Novartis

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global antidepressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antidepressant market

Detailed Segmentation-

• By Drug Class
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Fluoxetine
  • Sertraline
  • Others
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Venlafaxine
  • Duloxetine
  • Others
  • Tricyclic Antidepressants (TCAs)
  • Amitriptyline
  • Imipramine
  • Others
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Phenelzine
  • Tranylcypromine
  • Others
  • Atypical Antidepressants
  • Bupropion
  • Trazodone
  • Others
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson
  • Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Antidepressant Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Antidepressant Market, By Drug Class, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fluoxetine
• Sertraline
• Others
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Venlafaxine
• Duloxetine
• Others
• Tricyclic Antidepressants (TCAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Amitriptyline
• Imipramine
• Others
• Monoamine Oxidase Inhibitors (MAOIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phenelzine
• Tranylcypromine
• Others
• Atypical Antidepressants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bupropion
• Trazodone
• Others

6. Global Antidepressant Market, By Route of Administration, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Antidepressant Market, By Distribution Channel, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Antidepressant Market, By Region, 2021 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Eli Lilly and Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Market Strategies
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Research Methodology

• References
• Research Methodology
• About us and Sales Contact